NCT02211976已完成3 期
Comparative Efficacy and Tolerability of Bisacodyl Sugar Coated Tablets, Simeticone Chewing Tablets and the Combination of Both in the Treatment of Constipation and Bloatedness: an Open, Randomised, Parallel Group Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 30
- 主要终点
- Change in bloatedness score on a 4-point-scale
研究概览
简要总结
Pilot study to evaluate the efficacy and tolerability of the combined treatment of bisacodyl and simeticone compared with the efficacy and tolerability of the single products in patients suffering from constipation and bloatedness
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of constipation, defined as acute and habitual constipation; concomitantly patient must have complaint of bloated feeling
- •Patient was to be 18 years of age or older
- •Females who were of child bearing potential must have a negative pre-study urine pregnancy test and must be using oral or barrier contraceptive methods throughout the study. If oral contraceptives were used, the patient must be using them for at least 3 months prior to enrolment into the study
- •Patient must be willing to maintain a diary throughout the study
- •Patient must be otherwise in good health
- •Patient must sign an informed consent form which has been prepared in accordance with the Declaration of Helsinki
排除标准
- •Patient had drug-induced constipation resulting from drugs such as opioids, dopaminergics, antacids, anticholinergics or diuretics
- •Patient had a history of organic diseases of the colon such as tumors, stricture, and acute or chronic inflammatory diseases, ileus, acute surgical abdominal conditions such as acute appendicitis, or organic diseases of the rectum and anus such as fissures, fistulas, perianal abscesses, and eczema of the perianal skin
- •Patient exhibited evidence of active gastrointestinal disease
- •Patient was diagnosed as having intestinal obstruction, had any undiagnosed abdominal symptoms, or was in severe dehydration
- •Patient had a history of major gastrointestinal surgery
- •Patient had a history of hypersensitivity to substances of the triarylmethane class
- •Patient had a history of hypersensitivity to substances of the class of parahydroxybenzoic esters (para group allergy)
- •Patient had a history of drug or alcohol abuse
- •Patient had received bisacodyl for the treatment of another indication or in a previous study within the last 7 days before enrolment.
- •Patient had ingested any drug in the past week before enrolment that in the opinion of the investigator would have an effect on gastrointestinal motility (e.g. anti-cholinergic medications, opioids, smooth muscle relaxants or antacids)
- •Patient required the use of a drug, other than study drug, or dietary supplement to relieve the symptoms of constipation at any time during the baseline or treatment phases of this study
- •Patient was currently taking any form of tetracycline antibiotics
- •Patient was a nursing mother
- •Patient had received any investigational drug within the previous 4 weeks prior to enrolment
- •Patient had any condition that would interfere with the completion of this study, or that would decrease the likelihood of obtaining valid results
研究组 & 干预措施
Bisacodyl
Experimental
干预措施: Bisacodyl (Drug)
Simeticone
Experimental
干预措施: Simeticone (Drug)
Bisacodyl and simeticone
Experimental
干预措施: Bisacodyl (Drug)
Bisacodyl and simeticone
Experimental
干预措施: Simeticone (Drug)
结局指标
主要结局
Change in bloatedness score on a 4-point-scale
时间窗: baseline, 1 hour after drug administration
次要结局
- Number of withdrawals due to inadequate efficiency(up to 7 days)
- Time to defecation(up to 7 days)
- Investigator's assessment of overall tolerability on a 4-point-scale(up to 7 days)
- Change in bloatedness score on a 4-point-scale(baseline, 2 hours, 3 hours, at time of defecation)
- Number of patients with adverse events(up to 7 days)
- Patient's global assessment of efficacy on a 4-point-scale(up to 7 days)
- Number of patients with abnormal laboratory findings(up to 7 days)
- Patient's assessment of overall tolerability on a 4-point-scale(up to 7 days)
- Number of withdrawals due to safety reasons(up to 7 days)
- Number of patients with clinically significant changes in vital signs(up to 7 days)
研究者
相似试验
已完成
2 期
Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for ColonoscopyColonoscopy PreparationNCT02123017Cumberland Pharmaceuticals32
已完成
3 期
Titratable Dosing in Moderate to Severe AsthmaticsAsthmaNCT00651768AstraZeneca570
Unknown
不适用
Comparison of Bowel Cleansing Methods for Colonoscopy in Hospitalized PatientsComplaints IntestineNCT01528098Kangbuk Samsung Hospital600
撤回
不适用
Comparing 4L Golytely to 2L Golytely With 15mg Bisacodyl Regimens for Inpatient Colonic PreparationColonoscopyNCT01452737University of British Columbia
Unknown
2 期
A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung MicrobiotaChronic Obstructive Pulmonary DiseaseNCT02833480University of British Columbia69